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Losartan in patients with type 2 diabetes and proteinuria: Ob- patients. This practice was based on studies showing that
servations from the RENAAL Study. ACE inhibitors reduced renal outcomes in patients with
Background. Recently, the Reduction of Endpoints in NIDDM type 1 diabetes [1] and reduced proteinuria in type 2 dia-with the Angiotensin II Antagonist Losartan (RENAAL) Study
betes. However, a lack of data showing a treatment effectdemonstrated the benefit of losartan in reducing renal out-
of any agent on the progression of renal disease to end-comes in patients with type 2 diabetes and proteinuria. Addi-
tional questions concerning the reduction of proteinuria and stage renal disease (ESRD) or death, in combination
its relationship to end-stage renal disease (ESRD) as well as with lack of evidence that proteinuria is a surrogate for
cardio-renal outcomes and the safety and tolerability of losar- these endpoints, has provided a clear need to evaluatetan remain to be addressed.
the role of specific blockade of angiotensin II (Ang II)Methods. Three analyses were performed: (a) the impact of
in type 2 diabetic patients.losartan on the relationship between the reduction of protein-
uria and ESRD; (b) a time-to-event analysis of the cardio-renal The angiotensin II receptor antagonists (AIIAs), such
composite endpoint of ESRD, myocardial infarction, stroke or as losartan, represent the newest class of antihyperten-
all-cause death; and (c) additional analyses of adverse events, sive agents that provide highly specific blockade of theparticularly in patients with serum creatinine 2.0 mg/dL.
renin-angiotensin-aldosterone system (RAAS); losartanResults. After adjusting the values for proteinuria over the
as the first drug of this class is well suited for evaluationentire study, the reduction of proteinuria accounted for approx-
imately half of the treatment effect of losartan on the risk of renal protection. Losartan has been reported to be
reduction for ESRD. In addition, losartan was associated with efficacious in reducing blood pressure in renally impaired
a 21% risk reduction for the composite cardio-renal outcome patients, and is generally well tolerated in this patient(P 0.003). The addition of losartan to a conventional antihy-
population. Importantly, because of its dual eliminationpertensive regimen did not increase the overall incidence of
the initial dose of losartan does not require adjustmentadverse events, regardless of severity of renal impairment.
Conclusions. Losartan significantly reduced the risk of cardio- in patients with different degrees of renal impairment
renal outcomes and was well tolerated by patients, including including dialysis patients [2]. Experimental data in rats
those with serum creatinine levels 2.0 g/dL. In addition, al- demonstrated that losartan reduced glomerulosclerosisthough this study shows that the reduction of proteinuria does
in models of diabetic and non-diabetic renal disease [3–6].not completely explain the impact of intervention on outcomes
Further, in clinical studies losartan reduced proteinuriasuch as ESRD, reduction of proteinuria must remain an impor-
tant consideration when treating patients with type 2 diabetes in diabetic and non-diabetic patients while maintaining
and nephropathy. However, the reduction of outcomes such the glomerular filtration rate. In addition, several studies
as ESRD should remain the goal of therapy when evaluating have shown the safety and tolerability of losartan in hyper-renal protection in this patient population.
tensive patients with underlying kidney disease [7–13].
Recently, the Reduction of Endpoints in NIDDM with
the Angiotensin II Antagonist Losartan (RENAAL) StudyThe role of angiotensin II on the pathogenesis and
showed that losartan reduced the risk of developing thethe progression of renal disease has been demonstrated
primary composite endpoint of doubling of serum creati-in experimental models of diabetes. Until recently, an-
nine, end-stage renal disease (ESRD), or all-cause deathgiotensin converting enzyme (ACE) inhibitors were con-
by 16.1% (P  0.02) [14]. In addition, losartan reducedsidered the treatment of choice for patients with type 2
the risk for ESRD alone (risk reduction 28.6%, P diabetes and nephropathy without evidence that ACE
0.002) and for the combined endpoint of ESRD or deathinhibitors reduce the incidence of renal outcomes in these
(risk reduction 19.9%, P  0.01). Losartan was associ-
ated with a 34.3% decrease in proteinuria (P  0.001)
when compared to placebo and also reduced the rate of 2002 by the International Society of Nephrology
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decline in renal function by 18.5% (P 0.01), as assessed trough sitting blood pressure was140/90 mm Hg (“usual
therapy”).by the reciprocal of the serum creatinine concentration.
The cardio-renal composite endpoint was time toA secondary objective of RENAAL was the effect of
ESRD, MI, stroke, or all-cause death, whichever oc-losartan on cardiovascular morbidity and mortality. There
curred first. Every patient was counted only once evenwas no significant difference between losartan and pla-
if they had multiple events. A Cox regression modelcebo for the composite cardiovascular morbidity and
[16] that included baseline proteinuria as a stratificationmortality endpoint, which was a combined endpoint of
factor, and the treatment effect and geographic locationmyocardial infarction (MI), stroke, hospitalization for
as a covariate, was used to determine the hazard ratioheart failure, hospitalization for unstable angina, coro-
between losartan- and placebo-treated groups for thenary or peripheral revascularization or cardiovascular
composite cardio-renal endpoint. Analysis was by thedeath (risk reduction 9.6%, P  0.253).
intention-to-treat principle and all randomized patientsSeveral interesting questions remain, among which are
were included from randomization through study termi-the role of the secondary endpoint of reduction of pro-
nation date. The relationship between proteinuria reduc-teinuria in explaining the protective effect of losartan
tion over the entire study and treatment effect on ESRDand the impact of therapy on cardio-renal outcomes in
also was explored using a similar Cox model with thethis population. Further, the RENAAL database pro-
additional term of proteinuria (natural logarithm) in-vides a unique opportunity to study the side effect profile
cluded in the model as a time-varying covariate. For allof Ang II blockade in a high risk population of type 2
outcomes, a P value of 0.05 was considered significantdiabetic patients with nephropathy.
and all statistical tests were two-sided.This article discusses three separate topics. The first
pre-specified analysis examines the impact of losartan
on the relationship between the reduction of proteinuria RESULTS
and ESRD to determine whether the effect of losartan Baseline data have been described previously [15].
on ESRD could be explained by a reduction of protein- The effects of losartan on proteinuria were apparent
uria. The second evaluation is a post-hoc analysis to at three months (reduction of 29.1%, P  0.001) and
examine the effects of losartan on the composite end- persisted throughout the study: reduction from year 1
point of the cardiovascular and renal outcomes of ESRD, to study completion ranged from approximately 35% to
MI, stroke or all-cause death, whichever event occurred 39% (all values P  0.001). To examine whether or not
first. Due to the RENAAL study design, primarily as a reduction of proteinuria was a good predictor for the
renal-protection study, the population studied was com- treatment effect of losartan on ESRD, the impact of
prised of patients at high risk for progression of renal reduction of proteinuria was investigated. When protein-
disease. In addition to renal events, cardiovascular events uria was adjusted based on the values over the entire
are common in this patient population. This analysis study, the estimated risk reduction for ESRD was re-
would allow us to examine the occurrence of cardiovas- duced from 28.6% to 14.1%. This demonstrates that the
cular events prior to ESRD and includes ESRD as a treatment effect of losartan on ESRD is only partially
competing event to cardiovascular outcomes. The third explained by the reduction of proteinuria.
analysis focuses on the safety and tolerability of losartan The impact of losartan on the clinical outcomes of
in the RENAAL patient population with specific refer- ESRD, MI, stroke or all-cause mortality is shown in
ence to patients with serum creatinine levels2.0 mg/dL. Figure 1. In this time-to-event analysis, losartan was asso-
ciated with a 21% risk reduction for this composite end-
point (P  0.003).METHODS
Adverse experiences, regardless of causality, occurred
Study design in 95.3% and 95.7% of patients in the losartan and pla-
The RENAAL study design, inclusion/exclusion crite- cebo groups, respectively. The overall incidence of ad-
ria, and the treatment regimen have been reported in verse experiences leading to discontinuation was lower
detail elsewhere [14, 15]. Briefly, this was a double-blind, in the losartan group (19%) compared with the placebo
randomized, placebo-controlled study in which a total group (24.3%; risk reduction 0.78, 95% CI 0.65, 0.95).
of 1513 male and female patients aged between 31 and 70 For the total RENAAL population there were no sig-
years with type 2 diabetes and proteinuria were followed nificant differences between the two groups for the inci-
over a mean of 3.4 years. Patients were stratified according dence of anemia, hypoglycemia, hyperglycemia, or acute
to baseline proteinuria and, after a six-week screening renal failure. However, significantly more patients in the
period, randomized to either losartan (50 mg titrated to losartan group developed hyperkalemia (losartan 24.2%
100 mg once daily) or placebo, in addition to open-label, vs. placebo 12.3%, P 0.001), whereas significantly more
placebo-treated patients developed hypokalemia (losar-non-RAAS blocking, antihypertensive medication if the
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factor for the progression of renal disease and reduction
of proteinuria is an important therapeutic goal in patients
with glomerular disease. Many have suggested that re-
duction of proteinuria should be considered a surrogate
for renal protection and a marker to demonstrate the
therapeutic effect of agents on the progression of renal
disease to ESRD. Such data are not available in type 2
diabetes. In the present study, we examined this concept,
and analysis of RENAAL data shows that while losartan
reduces both proteinuria and the risk of ESRD, the treat-
ment effect of losartan on slowing the progression of
renal disease to ESRD can only be partially explained
by a reduction in proteinuria during the study. It is impor-
tant to note that further, more specific analyses of the
RENAAL database are being done to evaluate this ob-
servation and answer this question more definitively.
Nevertheless, the current data show that proteinuria re-
Fig. 1. Composite of clinically irreversible cardiovascular and renal
duction do not provide a full explanation of the renaloutcomes. Symbols are: (dotted line) placebo; (solid line) losartan. Risk
reduction was 21.2% (7.8, 32.6); P  0.003. protective effect of losartan. Perhaps one of the most
important findings from RENAAL is that delaying
ESRD or death as an outcome is achievable in clinical
trials conducted in patients with type 2 diabetes and
tan 2.5% vs. placebo 4.7%, P  0.013). Increased levels nephropathy. As such, delaying ESRD or death should
of potassium led to discontinuation of losartan in 1.1% be the goal of therapy for all future clinical studies of
of patients as opposed to 0.5% of patients in the placebo renal protection.
group. The coexistence of diabetes and hypertension substan-
Patients whose serum creatinine levels are2.0 mg/dL tially increases the risk of cardiovascular events, cardio-
are thought to be at higher risk of complications such vascular mortality and total mortality, and cardiovascu-
as acute renal failure, anemia and hyperkalemia. The lar disease is the most common cause of death in diabetic
results demonstrated that the risk of anemia and acute patients [18]. At present, no studies have demonstrated
renal failure did not increase in patients treated with a positive effect of any antihypertensive therapy on the
losartan with renal impairment. As expected, patients cardiovascular mortality or morbidity in pre-ESRD pa-
with decreased renal function had a higher incidence tients with type 2 diabetes. Although cardiovascular out-
of hyperkalemia, and losartan was associated with an comes were not the primary endpoint in RENAAL, this
increased incidence of hyperkalemia in patients whose post-hoc analysis shows that losartan significantly re-
serum creatinine was 2.0 mg/dL (losartan 10.5 vs. pla- duced the composite clinical outcome of renal and car-
cebo 2.5%). diovascular events of ESRD, MI, stroke, or all-cause
mortality in this population. This analysis evaluates the
treatment effects of losartan not only on ESRD, but onDISCUSSION
cardiovascular outcomes prior to ESRD. It should be
RENAAL and Irbesartan Diabetic Nephropathy Trial noted that dialysis introduces many other cardiovascular
(IDNT) were the first studies to examine the specific risk factors to these patients. These data demonstrate
blockade of the RAAS by an angiotensin II receptor the renal- and cardio-protective benefits of losartan in
antagonist and the effects of such blockade on progres- patients prior to the complications brought on by dialysis.
sion of renal disease to ESRD [17]. Both studies demon- Diabetic patients with nephropathy are at an increased
strated that angiotensin II blockade reduced the primary risk of adverse experiences in general; this is consistent
composite endpoint of doubling of serum creatinine, with RENAAL data, which showed the majority of pa-
ESRD, or death and reduced proteinuria [14, 17]. In tients in both treatment groups reported at least one ad-
RENAAL, losartan significantly reduced the risk of de- verse experience, regardless of causality. In RENAAL,
veloping ESRD and ESRD/death in this population. the addition of losartan to a conventional antihyperten-
Since RENAAL demonstrated the effect of losartan on sive regimen did not increase the overall incidence of
outcome of ESRD, we were able to evaluate the relation- adverse events. Fewer patients treated with losartan dis-
ship between changes in proteinuria with losartan and continued due to adverse events compared with placebo.
this important clinical outcome. Considering the population, select adverse events were
pre-specified for formal analysis: acute renal failure, hyp-Proteinuria has been identified as an independent risk
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